Tesamorelin is a synthetic peptide studied in laboratory research as a stabilised analogue of growth-hormone-releasing hormone (GHRH) — a modification of the native hGRF(1-44) sequence with an N-terminal trans-3-hexenoyl group that resists enzymatic cleavage. Elite AU Peptides supplies it strictly for in-vitro and laboratory research use only — not for human or animal consumption, not a therapeutic good, and not TGA-approved. We make no medical, therapeutic, or body-composition claim about it.

How is tesamorelin different from CJC-1295?

Both are GHRH-receptor-active analogues, but they carry different stabilising chemistry: tesamorelin uses an N-terminal trans-3-hexenoyl modification on the hGRF(1-44) backbone, while CJC-1295 (no DAC) is a 30-residue hGRF(1-29) analogue (Mod GRF 1-29) with D-Ala2 and other substitutions. See the CJC-1295 GHRH guide for that compound.

Is tesamorelin TGA-approved in Australia?

Tesamorelin is a structural analogue of a regulated medicine. The material supplied here is not TGA-approved, is not a therapeutic good, and is supplied for in-vitro laboratory research use only — not for human or animal consumption, with no medical, therapeutic, or body-composition claim.

How is research-grade tesamorelin tested?

Every batch is independently HPLC-tested by Janoshik Analytical before it is listed. The certificate is published on the product page and in the lab-reports library — independently verifiable at janoshik.com; nothing is listed without a certificate on file.

How is tesamorelin reconstituted, stored and shipped?

Reconstitute the lyophilised vial with bacteriostatic water — a 10mg vial in 5mL yields a 2mg/mL working stock. Store the powder at −20°C protected from light; once reconstituted, refrigerate at 2–8°C. Dispatched AU-domestic, free shipping over $100, same-day dispatch before 12pm AEST. Supplied strictly for laboratory research use only.

[ GLP-1 / incretin research ]

Tesamorelin in Australia: a GHRH-analogue research guide

What tesamorelin is — a stabilised analogue of growth-hormone-releasing hormone (GHRH) referenced across growth-hormone-axis research — where it sits in the literature, and how research-grade material is HPLC-verified. Receptor-research framing only; research use only.

7 min read · Updated 22 July 2026

Tesamorelin GHRH-analogue research peptide vial — 10mg / 20mg, independently HPLC-tested, COA on file

[ Research use only · Not for human consumption ]

Tesamorelin in Australia. Tesamorelin is a synthetic peptide studied in laboratory research as a stabilised analogue of growth-hormone-releasing hormone (GHRH) — a modification of the native hGRF(1-44) sequence. This guide is a research-reference summary for Australian researchers, framed strictly around GHRH-receptor pharmacology. It makes no medical, therapeutic, or body-composition claim.

What tesamorelin is

Tesamorelin is a synthetic analogue of the 44-residue growth-hormone-releasing hormone, modified at the N-terminus with a trans-3-hexenoyl group and carrying a C-terminal amide. That N-terminal modification is what distinguishes it from native hGRF(1-44): it confers resistance to dipeptidyl-peptidase-IV cleavage and extends the peptide’s in-vitro stability and half-life, which is what makes it a useful GHRH-receptor reference agonist.

What the published research reports

The non-clinical pharmacology — the trans-3-hexenoyl modification and its DPP-IV-resistance and stability profile — was characterised by Ferdinandi and colleagues (Basic & Clinical Pharmacology & Toxicology, 2007). Its action on endogenous, pulsatile growth-hormone secretion (the pharmacodynamic readout that makes it a useful GHRH-receptor reference agonist) was examined by Stanley and colleagues (The Journal of Clinical Endocrinology & Metabolism, 2011). As a stabilised GHRH-receptor agonist, tesamorelin is used as a reference standard in growth-hormone-axis research — for receptor-binding work and downstream somatotrophic-pathway signalling studies.

Tesamorelin among the GHRH analogues

Tesamorelin is one of two GHRH-active compounds in the catalogue. It differs from CJC-1295 (no DAC) in its stabilising chemistry — an N-terminal trans-3-hexenoyl modification on the hGRF(1-44) backbone versus CJC-1295’s D-Ala2 and other substitutions on a 30-residue hGRF(1-29) backbone. See the CJC-1295 GHRH guide for that compound, and the retatrutide vs tesamorelin comparison for how it contrasts with the triple incretin agonist in the same metabolic category.

Identity, purity and compliance

Tesamorelin is stocked in 10mg and 20mg lyophilised vials, each batch independently HPLC-tested by Janoshik before listing, with the certificate published on the product page and in the lab-reports library. Tesamorelin is a structural analogue of a regulated medicine; the material here is not TGA-approved, is not a therapeutic good, and is supplied strictly for in-vitro and laboratory research use only — not for human or animal consumption, with no medical, therapeutic, or body-composition claim.

[ Frequently asked ]

GLP-1 / incretin research — questions researchers ask.

What is tesamorelin?: Tesamorelin is a synthetic peptide studied in laboratory research as a stabilised analogue of growth-hormone-releasing hormone (GHRH) — a modification of the native hGRF(1-44) sequence with an N-terminal trans-3-hexenoyl group that resists enzymatic cleavage. Elite AU Peptides supplies it strictly for in-vitro and laboratory research use only — not for human or animal consumption, not a therapeutic good, and not TGA-approved. We make no medical, therapeutic, or body-composition claim about it.
What research is tesamorelin associated with?: Its non-clinical pharmacology — the trans-3-hexenoyl modification and its DPP-IV-resistance and stability profile — was characterised by Ferdinandi and colleagues (Basic & Clinical Pharmacology & Toxicology, 2007). Its action on endogenous, pulsatile growth-hormone secretion (the pharmacodynamic readout that makes it a useful GHRH-receptor reference agonist) was examined by Stanley and colleagues (The Journal of Clinical Endocrinology & Metabolism, 2011). It is studied in vitro as a GHRH-receptor research tool, not as a treatment.
How is tesamorelin different from CJC-1295?: Both are GHRH-receptor-active analogues, but they carry different stabilising chemistry: tesamorelin uses an N-terminal trans-3-hexenoyl modification on the hGRF(1-44) backbone, while CJC-1295 (no DAC) is a 30-residue hGRF(1-29) analogue (Mod GRF 1-29) with D-Ala2 and other substitutions. See the CJC-1295 GHRH guide for that compound.
Is tesamorelin TGA-approved in Australia?: Tesamorelin is a structural analogue of a regulated medicine. The material supplied here is not TGA-approved, is not a therapeutic good, and is supplied for in-vitro laboratory research use only — not for human or animal consumption, with no medical, therapeutic, or body-composition claim.
How is research-grade tesamorelin tested?: Every batch is independently HPLC-tested by Janoshik Analytical before it is listed. The certificate is published on the product page and in the lab-reports library — independently verifiable at janoshik.com; nothing is listed without a certificate on file.
How is tesamorelin reconstituted, stored and shipped?: Reconstitute the lyophilised vial with bacteriostatic water — a 10mg vial in 5mL yields a 2mg/mL working stock. Store the powder at −20°C protected from light; once reconstituted, refrigerate at 2–8°C. Dispatched AU-domestic, free shipping over $100, same-day dispatch before 12pm AEST. Supplied strictly for laboratory research use only.

[ Referenced in this guide ]

Shop the compounds

[ Keep reading ]

More research guides

Elite AU Peptides supplies research peptides and related compounds for laboratory and in-vitro research use only. Products are not therapeutic goods, are not TGA-approved, and are not for human or animal consumption. Nothing on this site constitutes medical advice or a therapeutic claim. Purchasers must be 18 years or older and are responsible for complying with all applicable laws in their jurisdiction.